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In the absence of efﬁcient diagnostic and therapeutic tools, Alzheimer’s disease (AD) is a major public
health concern due to longer life expectancy in the Western countries. Although the precise cause of AD
is still unknown, soluble b-amyloid (Ab) oligomers are considered the proximate effectors of the synaptic
injury and neuronal death occurring in the early stages of AD. Ab oligomers may directly interact with
the synaptic membrane, leading to impairment of synaptic functions and subsequent signalling
pathways triggering neurodegeneration. Therefore, membrane structure and lipid status should be
considered determinant factors in Ab-oligomer-induced synaptic and cell injuries, and therefore AD
progression. Numerous epidemiological studies have highlighted close relationships between AD inci-
dence and dietary patterns. Among the nutritional factors involved, lipids signiﬁcantly inﬂuence AD
pathogenesis. It is likely that maintenance of adequate membrane lipid content could prevent the
production of Ab peptide as well as its deleterious effects upon its interaction with synaptic membrane,
thereby protecting neurons from Ab-induced neurodegeneration. As major constituents of neuronal
lipids, n-3 polyunsaturated fatty acids are of particular interest in the prevention of AD valuable diet
ingredients whose neuroprotective properties could be essential for designing preventive nutrition-
based strategies. In this review, we discuss the functional relevance of neuronal membrane features with
respect to susceptibility to Ab oligomers and AD pathogenesis, as well as the prospective capacities of
lipids to prevent or to delay the disease.
 2009 Elsevier Masson SAS. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is a progressive dementia that mani-
fests in early stages as a profound inability to form new memories.
Age is the major risk factor for the non-familial form of AD (up to
99% of cases), which at least partly explains the dramatic increase in
AD prevalence in countries where life expectancy is growing [1].er’s disease; ApoE, apolipo-
hidonic acid; cPLA2, cytosolic
hexaenoic acid; EPA, eicosa-
tentiation; PS1, presenilin-1;
osine-1-phosphate; SMase,
AIA – INPL, Nancy-Universite´,
-Nancy, France. Tel.: þ33 383
(T. Oster).
son SAS. All rights reserved.Many questions about pathogenesis of this devastating disease still
remain unanswered and satisfying therapeutic options are few [2].
Given the heavy individual and societal burdens inﬂicted by AD,
there is enormous medical need for the development of novel
therapeutic strategies that target or even better prevent from the
mechanisms leading to dementia. In this context, it becomes
essential to identify the molecular actors and pathways involved in
AD pathogenesis.
Due to the progressive and – yet – irreversible nature of AD, very
early stages (preclinical and mild cognitive impairment) may be
due to synaptic dysfunction caused by Ab peptide under soluble
oligomeric form, long before widespread synaptic loss and neuro-
degeneration. Indeed, clinical studies have shown that soluble Ab
levels rather than amyloid deposits are better correlated with
dementia severity [3]. Furthermore, in the brain of AD patients, Ab
oligomeric forms mainly target synapses affected early in the
pathogenesis [4]. Cognitive deﬁcits appear before amyloid deposi-
tion in AD transgenic mice models [5], which strongly implicate
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term potentiation (LTP), a paradigm for memory [6], as well as
cognitive functions [7].
Fusogenic properties of soluble Ab suggest that interaction with
plasma membrane occurs among the initial events leading to
impairment of synaptic functions and subsequent neurodegeneration
[8]. It is thus essential to identify the biological factors that could
modulate these early interactions and their noxious consequences.
Besides age and gender, education level and social activities, dietary
parameters represent common risk factors for neurodegenerative and
cardiovascular diseases, leading to the idea that nutrition could offer
powerful tools for delaying onset of AD or slowing its progression.
Among them, lipid status hasbeen identiﬁed as a key parameter inAD
pathogenesis by numerous epidemiological, clinical, animal or
cellular studies [9]. This is especially the case for docosahexaenoic
acid (DHA; n-3, C22:6), a fatty acid essential for cerebral functions and
whose decline has been reported in the brain and plasma of AD
patients [10].
2. Lipids inﬂuence neuronal susceptibility to amyloid stress
2.1. Membrane architecture is determinant for Ab
neurotoxicity and production
A growing body of evidences supports the notion that
membrane destabilization by Ab oligomers may represent the
primary mechanism of pathogenesis. Indeed, exposure to soluble
Ab causes a rapid and reversible leakage of calcium that can be
inhibited by anti-oligomer antibody. Such an increased lipid
bilayer conductance without forming discrete pores suggests that
Ab oligomers could directly induce a profound remodelling of
plasma membrane. In that way, we have shown that exogenous
cholesterol and DHA protect cortical neurons in primary cultures
from Ab-induced apoptosis, while cholesterol depletion increases
Ab-oligomers neurotoxicity [11,12]. Since steric incompatibility of
the rigid steroid moiety for highly disordered DHA chain
promotes lateral segregation of lipids into rafts [13,14], it can be
deduced that membrane lipid status is strongly involved in
neuron susceptibility to Ab oligomers and therefore representsFig. 1. Alternative processing of APP. APP is mainly metabolised through the non-amyloidog
a secreted neurotrophic protein called sAPPa. On the other hand, the amyloidogenic pathway
occurs in rafts represented here by membrane domains enriched in cholesterol (purple hexa goal for prevention. Accordingly, it is well known that inheri-
tance of apolipoprotein 34 allele (ApoE4) is a major risk factor for
sporadic AD [15]. ApoE proteins belong to the family of plasma
lipid-binding proteins involved in triglycerides and cholesterol
transport and delivery, but it is also worthy to note that ApoE
proteins also contribute to the clearance of Ab peptide through
binding to lipoprotein receptors [16].
Although the link between ApoE4, cholesterol and AD is still not
clear, it becomes obvious that cholesterol can modulate AD path-
ogenesis by inﬂuencing Ab production and neurotoxicity [9]. Ab
peptides are derived from proteolytic cleavage of the membrane-
bound amyloid protein precursor (APP). APP is metabolised by two
possible pathways: the non-amyloidogenic pathway involves
a sequential cleavage of APP by a- and b-secretases, leading to the
release of a secreted neurotrophic APP ectodomain called sAPPa,
while the amyloidogenic pathway results in Ab release as well as
loss-of-function of truncated sAPPa [17]. As the a- and b-secretases
compete for the same substrate, distribution of APP between the
two alternative pathways is thus tightly regulated. Numerous
studies support the hypothesis that dynamic partitioning of APP
and its proteolytic enzymes in different membrane domains could
be the main regulatory mechanism involved (Fig. 1). Accordingly, it
was found that b- and g-secretase activities are concentrated and
optimized in lipid rafts, while a-secretase and APP aremainly found
in non-raft regions [18]. Consistent with that, depletion in choles-
terol which is highly enriched in rafts has been demonstrated to
decrease Ab production [19], leading to the exciting perspectives of
statin-based treatment as a mean to lower cholesterol levels.
Statins have been reported to reduce AD risk [20,21] and to prevent
Ab-induced neuronal loss and memory impairment [22], but
contradictory data have also been published [23]. This suggests that
the appropriateness of statin therapy is not established at this time
[24,25] and the fact that a moderate decrease in cholesterol levels
results in increased Ab production in primary hippocampal neurons
[26] indicates that the link between cholesterol and AD requires to
be more clearly elucidated.
In this context, DHA has been recently demonstrated to promote
the non-amyloidogenic pathway, resulting in reduced Ab levels in
AD cellular models [27]. Though dietary DHA clearly leads toenic pathway involving a sequential cleavage by a- and b-secretases, leading to release
requires b- and g-secretase activities and leads to Ab production. This pathway mainly
agons) and gangliosides (with red tails).
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membrane structure is still debated as it has been detected in
cholesterol-rich domains [28] albeit its non-raft physiochemical
properties [14]. These data altogether suggest that membrane lipid
status is strongly involved in APP processing and that any pertur-
bations could lead to deleterious cascades. Management of lipid
status thus represents a very promising objective for preventing Ab
interactionwithmembrane and deleterious outcomes, as well as Ab
production in the central nervous system.
2.2. Neuronal cell death induced by Ab oligomers
involves lipid mediators
2.2.1. Phospholipase A2–arachidonic acid pathway
Initiation of inﬂammatory processes takes place during the
earliest stages of AD and is associated with an increase in free fatty
acid levels, suggesting that phospholipases may play a crucial role
in the production of second messengers involved in deleterious
cascades [29]. Accordingly, increased immunoreactivity of the
cytosolic calcium-dependent phospholipase A2 (cPLA2) is observed
in AD cortex as compared with that of age-matched control
subjects. Treatments of primary culture of cortical neurons with
low concentrations of Ab oligomers lead to a precocious activation
of cPLA2 and rapid arachidonic acid (ARA; n-6, C20:4) release,
demonstrating that neuro-inﬂammatory cascades could be initi-
ated by soluble Ab [30]. Indeed, ARA acts as a second messenger
that directly regulates a number of cellular processes, including
apoptotic pathways, and serves as a precursor for the production of
eicosanoids, a variety of other lipid mediators. Inhibition of cPLA2
activation or expression upon exposure to Ab oligomer has been
shown to signiﬁcantly protect neurons from subsequent cell death,
which suggests that the control of cPLA2 activity could be an
interesting therapeutic target for AD.
2.2.2. Sphingomyelinases–ceramide pathway
Altered sphingolipid metabolism has been reported in AD brain,
including elevated acid sphingomyelinase (SMase) and acid
ceramidase associated with lower sphingomyelin levels and higher
ceramide and sphingosine levels [31]. Ceramides and sphingosineFig. 2. Lipid mediators in Ab neurotoxicity. This cartoon depicts the pivotal contribution of
Upon their interaction with the lipid bilayer, a very rapid cellular response is initiated, i
subsequent ARA release. Besides the pro-inﬂammatory cascade mediated by COX/LOX-produ
activation, detrimentally to sphingolipids and especially to S1P whose production and cellare important second messengers that regulate diverse cellular
processes, including cell growth and differentiation, and display
potent proapoptotic properties. Once produced, ceramides could
also form signalling platforms that have been shown to cluster
receptor molecules transmitting apoptotic stimuli into the cell [32].
In vitro, Ab oligomers induce the activation of both neutral and acid
SMases through a redox-sensitive cPLA2–ARA dependent pathway,
which results in apoptotic cell death [33]. Ceramides have also been
shown to stabilize the b-site APP cleaving enzyme BACE-1, thereby
promoting Ab production [31]. Interestingly, sphingosine-1-phos-
phate (S1P), an anti-apoptotic molecule able to inhibit Ab-induced
ASM activation and subsequent neuronal apoptosis, is also
decreased in AD brain [31,33]. It is likely that elevated ceramides
and sphingosine as well as lower S1P create a proapoptotic
environment in AD brain that takes part in neuronal death (Fig. 2).
3. DHA supplementation studies strongly suggest
potential for AD prevention
3.1. DHA prevents neuronal cell death through
various protective mechanisms
Since conversion from a-linolenic acid to DHA is very low in
human, DHA is now increasingly considered an essential fatty acid
that must be provided from diet [34]. This is especially true in
elderly whose neuronal membranes often display a deﬁcit in DHA
[10]. Several studies have established that moderate ﬁsh
consumption as a proxy of n-3 polyunsaturated fatty acids (PUFAs)
is associated with a reduced risk of impaired cognitive functions.
This neuroprotective effect is usually described to rely on 4 distinct
and interconnected molecular mechanisms: (i) regulation of gene
expression, (ii) anti-oxidative and (iii) anti-inﬂammatory effects, as
well as (iv) membrane remodelling.
3.1.1. Regulation of gene expression
The ﬁrst reported effect of dietary PUFA-induced differential
gene expression pattern in the brain has been reported on myeli-
nation process [35]. A nutrigenomic approach has then revealed
signiﬁcant changes in the expression of several genes including thelipids in signalling of apoptotic cell death induced in neurons exposed to Ab oligomers.
nvolving an oxidative stress and a calcium inﬂux that leads to cPLA2 activation and
ced eicosanoids, ceramide-enriched membrane domains are favoured thanks to SMase
protective properties are prevented.
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aged rats fed with ﬁsh oil [36]. The number of genes whose
expression has been modiﬁed as well as the extent of these
modiﬁcations depends on the conditions of the supplementation,
which suggests that high PUFA intake must be well ﬁtted in terms
of both duration and level to have a signiﬁcant effect on human
health.
3.1.2. Oxidative stress
Increasing levels of oxidative stress markers appear early in AD
pathogenesis implying soluble Ab oligomers. Some reports have
concluded that DHA or ﬁsh oil supplementation can result in
antioxidant effects in rat corpus striatum [37] as well as in hippo-
campus and cortex of an ADmodel rat [38]. However, DHA provided
as free fatty acid failed to prevent the oxidative stress induced in
vitro in neurons exposed to soluble Ab peptides and rather seems to
favour oxidation, radical formation and subsequent damages [12],
which could at least partially be explained by the high unsaturation
degree of this fatty acid.
3.1.3. Inﬂammatory process
Keeping in mind the importance of the inﬂammatory processes
in AD and the beneﬁcial impact of dietary intake of DHA on
inﬂammatory diseases such as asthma, it was worth to explore
whether DHA could modulate cPLA2 pathway. In vitro, DHA
pretreatment of neurons does not prevent Ab-induced ARA release,
suggesting that DHA does not inhibit cPLA2 activation, while
neurons are fully protected from Ab when cultured in media
supplementedwith DHA and pretreatedwith a cPLA2 inhibitor [12].
However, recent work demonstrated that DHA and eicosapentae-
noic acid (EPA; n-3, C20:5) are converted to bioactive mediators
named docosatrienes and resolvins, respectively [39]. The main
potent member of DHA metabolites is neuroprotectin D1 and has
been reported to decrease Ab peptide production as well as
apoptosis induced in vitro by Ab oligomers [40]. Interestingly,Table 1
Summarised description of n-3 PUFA dietary supplementation studies in aging/AD anim
Model Route of administration
and daily dose of DHA
Duration
Young and aged rats High-n-3 PUFA diet 10 mg DHA/d
(from tuna oil)
2 months
Adult male rats progeny from
female depleted or
not in PUFAs
High-n-3 PUFA diet (from tuna oil
or egg phospholipids)
2–3 month
Young and aged rats Intra-gastric injection of puriﬁed
ethyl-ester-DHA (10 mg DHA/d)
2 months
5-week old male rats Intra-gastric injection of puriﬁed
ethyl-ester-DHA (300 mg/kg/d)
3.5 months
25-week old rats Intra-gastric injection of puriﬁed
ethyl-ester-DHA (300 mg/kg/d)
3 months
18-month old rats Intra-gastric injection of puriﬁed
ethyl-ester-DHA (300 mg/kg/d)
0.5 month
Adult gerbils Intra-gastric injection of puriﬁed
ethyl-ester-DHA (50–300 mg/kg/d)
1 month
15-month old female mice Intra-gastric injection of puriﬁed
ethyl-ester-DHA (50–100 mg/kg/d)
1.7 months
3-week old male mice Palm oil (n-3-deﬁcient) or sardine oil
(n-3-abundant) diet chow
12 months
6-month old female 2  Tg
mice (APP  PS1)
High-DHA (0.5% DHA) diet chow 3 months
17-month old Tg2576 mice High-DHA (0.6% DHA) diet chow 3.5 months
17–19-month old Tg2576 mice High-DHA (0.6% DHA) diet chow 3.5 months
3-month old 3  TgAD mice High-DHA, [DHA þ DPA] or [DHA þ AA]
diet chow (n-6/n-3 ¼ 1/1)
3, 6 or
9 months
2-month old 2  Tg mice
(APP  PS1)
High-n-3 diet chow including 4% of
menhaden ﬁsh oil (n-6/n-3 ¼ 3.8/1)
4 monthssAPPa can induce neuroprotectin D1 generation, which allows
linking the decrease in the latter to the reduced production of
sAPPa observed in AD brain.
3.1.4. DHA and membrane incorporation
Due to its physicochemical features, DHA enrichment results in
higher membrane ﬂuidity and subsequently modulated activity of
membrane-associated proteins, as well as vesicle formation and
fusion. This could allow DHA modifying membrane architecture,
especially the number of lipid rafts as well as their distribution and
composition. In our in vitromodel, protection of rat cortical neurons
from Ab-induced apoptosis is observed by supplementing the
culture mediumwith nanomolar DHA concentrations, which likely
results in DHA enrichment of speciﬁc phospholipid species or
membrane microdomains [12]. Accordingly, immunocytochemical
analysis of raft-speciﬁc partners such as ganglioside M1 and
ﬂotillin-1 shows a membrane disorganisation in cortical neurons
exposed to soluble Ab oligomers, whereas normal intense ﬂuores-
cence labelling is obtained in neurons pretreated with DHA [41].
This could suggest that the apoptosis induced by Ab oligomers
involves structural and qualitative changes in lipid microdomains
that could be prevented in DHA-enriched membranes. Appropriate
studies to assess this hypothesis are in progress in our laboratory.
3.2. DHA supplementation potential has been proven
in Alzheimer’s disease models
Numerous dietary supplementation studies have been reported
in the literature. They mostly differ by the animal model, the route
of administration, the nature, the dose and the source of the PUFA
provided (puriﬁed DHA under ethyl-ester or phospholipid form,
DHA þ EPA, ﬁsh oil.) and the duration of the supplementation, as
summarised in Table 1. Most studies were performed either using
intra-gastric administration of puriﬁed ethyl-ester-DHA or ﬁsh oil
emulsiﬁed in 5% gum Arabic solution at concentrations rangingal models.
Main effects of DHA/n-3 PUFAs/ﬁsh oil References
Reversion of age-related impairments in LTP and
depolarisation-induced glutamate transmitter release
McGahon et al.
(1999) [42]
s Enhancement of the potassium chloride-evoked
release of acetylcholine in rat hippocampus
Aid et al.
(2005) [43]
Reversion of age-related alterations of phospholipid proﬁles Little et al.
(2007) [44]
Improvement of spatial cognition, increase in Fos
expression in rat CA1 hippocampus
Tanabe et al.
(2004) [45]
Increased synaptosomal membrane ﬂuidity, protection
from learning/memory impairments in Ab-infused rats
Hashimoto et al.
(2006) [46]
Promotion of neurogenesis in vitro and in vivo Kawakita et al.
(2006) [47]
Increase in dendritic spine density in hippocampus Sakamoto et al.
(2007) [48]
Improvement of age-related cognitive impairments,
increase in BDNF levels in hippocampus
Jiang et al.
(in press) [49]
Higher DHA level in brain, membrane synaptic ﬂuidity
and maze-learning ability
Suzuki et al.
(1998) [50]
Decrease in Ab load Oksman et al.
(2006) [51]
Protection from dendritic pathology and behavioural
deﬁcits, increased anti-apoptotic BAD phosphorylation
Calon et al.
(2004) [52]
Reduction of amyloid burden Lim et al.
(2005) [53]
Amelioration of Ab and Tau pathology
(after 3 months) via a mechanism involving PS1 levels
Green et al.
(2007) [54]
No improvement or protection of cognitive performance Arendash et al.
(2007) [55]
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comparing low DHA or high-n-6/n-3 molar ratio to high-DHA-diet.
It should be noted that elevated n-6/n-3 diets could induce
pro-inﬂammatory conditions and must hence be interpreted
carefully or compared with a well-ﬁtted standard diet adjusted to
present adequate n-6/n-3 ratio ranging from 4/1 to 10/1 [56].
3.2.1. Beneﬁcial impact of DHA in aging model
Changes in lipid composition such as the age-related decline in
DHA content can affect the biophysical features of the neuronal cell
membranes with subsequent cell signalling, enhancing their
sensitivity to various stresses. Depolarisation-induced neurotrans-
mitter release is particularly decreased in synaptosomes prepared
from the hippocampus of aged rats compared with those from
young animals. This decline is at least in part explained by an
increase in membrane rigidity and results in a poorer ability to
sustain LTP and promote synaptic plasticity [42]. It was also
demonstrated that a 2-month feeding program reversed the
age-related impairment of LTP, which could be due either to an
increase in synaptosomal ﬂuidity [46] or to optimisation of ion
channelling favoured by a more appropriate membrane environ-
ment [43]. Accordingly, some studies based on supplementation of
young and older rats with a daily dose of 10 mg of DHA have
reported an increase in the unsaturation index of old rat cortical
tissue to levels similar to those observed in young animals, which
thereby normalises age effect [44]. This response was associated
with a replenishment of the DHA-containing species, especially
phosphatidylinositol and phosphatidylserine, which could have
important implications for DHA biological functions since these
species are known to be involved in cell signalling and apoptosis.
Improvement of age-induced cognitive impairment could also be
explained by the formation of new dendritic spines. As a matter of
fact, a daily administration of DHA, but not of ARA was demon-
strated to lead to a signiﬁcant increase in spine density in the
primary apical dendrites of CA1 pyramidal neurons associated with
higher expression of pre- and post-synaptic proteins in hippo-
campus, a pivotal structure for memory process [48]. These authors
also highlighted the synergistic effect of DHA and phosphatide
precursors such as UMP or CDP-choline (citicoline) in terms of
neurogenesis and dendritic spine formation. The latter is of
particular interest as PC is the major phospholipid in the brain and
provides the PC moiety needed to synthesise sphingomyelin.
However, almost all precursors required by the brain being
obtained from the circulation, their blood levels can affect the
overall rate of PC-synthesis and thus inﬂuence synaptogenesis and
dendritic formation [57].
3.2.2. Beneﬁcial impact of DHA in AD models
Two types of methods are basically used to investigate DHA
potential beneﬁts against AD pathogenesis: acute Ab-oligomer
brain exposure in Ab-infused rat or AD transgenic mice models.
Depending on the transgene(s) involved, contradictory data were
obtained, especially for AD mice models. Indeed, while a DHA-diet
was shown to reduce amyloid burden and prevent from dendritic
pathology in Tg2576 mice [52,53] as well as in 3-month old
3  TgAD mouse models [54], no improvement in cognitive
performances of (APP)-sw þ PS1 double transgenic mice was
observed [55]. However, it is worth to note here that these ADmice
models have been conceived to mimic Ab overproduction as
observed in genetic cases of the familial form of disease and
therefore constitute a rather poor model for early stages of the
widespread sporadic disease. For this reason, several studies were
designed by using acute Ab-oligomer exposure only. Intra-gastric
administration of puriﬁed ethyl-ester-DHA emulsiﬁed in 5% gum
Arabic solution at 300 mg/kg/d was reported to preserve thelearning capacities of Ab-infused rats from impairment induced by
Ab oligomers. This neuroprotective effect was shown to be associ-
ated with a decrease in cholesterol/phospholipids molar ratio and
in lipid peroxidation, as well as an increase in synaptosomal DHA
content and in the number of newborn neurons in the entire
granule cell layer of dentate gyrus [46,47]. More recently, a new AD
mouse model has been validated in our laboratory, based on
a single stereotaxic injection of picomoles of soluble Ab oligomers
in the brain lateral ventricle, very close to the hippocampus [7].
Such a mouse then displays synaptic dysfunction and cognitive
deﬁcits, but neuronal death and neuroinﬂammation have not been
detected. This model closely resembles the earliest AD stages and
therefore represents a precious tool for evaluating the neuro-
protective potential of preventive approaches. Preliminary and
unpublished data obtained from this model indicate that dietary
supplementation with very low doses of DHA fully preserves the
learning and memory capacities from impairment induced by
Ab-oligomer injections.4. Conclusion
Sporadic Alzheimer’s disease is a pathology whose onset relies
upon the coincidence of a complex pattern of risk factors that could
render neurons particularly susceptible to soluble Ab oligomers. In
the brain of individuals prone to declare AD, neurons very likely
exhibit poor intrinsic resistance capacities that presumably result
at least partially from accumulation of oxidative damage as
postulated by the free radical theory of aging [58]. However,
a substantial body of evidence is growing, leading to consider that
AD pathogenesis can also be favoured as a consequence of altered
lipid status, similarly to other age-related syndromes including
cardiovascular diseases, diabetes and obesity. Therefore, AD could
reasonably be considered a lipid metabolism disease whose asso-
ciated dysfunctions accumulate for years as a result of deteriorated
nutritional quality of the Western diet. Along with longer lifespan,
this would lead to pathological brain ageing and explain elevated
prevalence of AD in our countries.
Interestingly, all these devastating afﬂictions can be appropri-
ately prevented by nutritional strategies, leading to predictable
modiﬁcations in the lipid content and status of target tissues and
brain particularly. Numerous studies have provided the exciting
emerging evidence that DHA is a potent neuroprotective fatty acid
that can prevent neuronal damage and cell death in vitro and
protect elderly as well as animal models from age- and Ab-induced
cognitive impairments in vivo. Elucidation of the molecular mech-
anisms and pathways responsible for these effects still requires
further investigations, for instance in order to explain the highly
heterogeneous effects reported in the literature for which apoE
genotype may be in part responsible as a possible determinant of
lipid responsiveness to DHA or ﬁsh oil intervention. Nonetheless,
DHA already appears a central compound in the view of designing
well-being diets for seniors. As membrane impairment also seems
to be a key event in other afﬂicting diseases, dietary lipids could be
regarded as valuable ingredients whose protective effects could be
of essential interest for designing new preventive strategies based
on nutritional approaches. This challenge is especially urgent for
AD due to the lack of really efﬁcient therapeutic drugs and
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